Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride.

Abstract

The pharmacy and therapeutics committee-based clinical evaluation can be a useful tool in the economic and functional effectiveness of a restrictive formulary system. We utilized this concept to evaluate a generic formulation of procainamide hydrochloride (PA) for admission to our formularies. The study performed was a randomized, single-blind, crossover comparison of the serum-concentration profiles of two preparations (Squibb vs. Ascot) of conventional-release PA. Ten outpatients requiring chronic PA therapy for the control of ventricular dysrhythmias were evaluated. The resultant dose-adjusted data showed no significant difference between mean serum PA concentrations at any sample time, area under the serum concentration-time curves, mean peak serum PA concentrations achieved, or peak-trough fluctuations. Relative bioavailability was calculated to be 0.972 +/- 0.59. The Ascot preparation demonstrated a delay of 15 minutes before the onset of absorption; however, it also showed an earlier tmax in comparison to the Squibb formulation. Generic substitution of Ascot PA in place of Squibb PA may be implemented with significant cost savings.

Statistics

02004002008200920102011201220132014201520162017
Citations per Year

209 Citations

Semantic Scholar estimates that this publication has 209 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kasmer1987ComparableSB, title={Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride.}, author={R J Kasmer and Asha Nara and John A. Green and Anil Chawla and Geoffrey M. Fleming}, journal={Drug intelligence & clinical pharmacy}, year={1987}, volume={21 2}, pages={183-6} }